Introduction {#Sec1}
============

Naïve T helper cells differentiate into a number of effector subsets that coordinate pathogen-specific immune responses including T helper 1 (T~H~1) and T follicular helper (T~FH~) cell populations. T~H~1 cells mediate immune responses to intracellular pathogens in large part through the production of the pro-inflammatory cytokine interferon-γ (IFN-γ), while T~FH~ cells aid in antibody-mediated immunity by activating B cells via cognate cell-cell interactions and secretion of the cytokine IL-21^[@CR1]--[@CR3]^. As with other T helper cell subsets, the differentiation of T~H~1 and T~FH~ cells is coordinated by the interplay between cell-extrinsic cytokine signals and cell-intrinsic transcription factor networks. For T~H~1 cells, IL-12-dependent activation of Signal Transducer and Activator of Transcription 4 (STAT4) drives the expression of the transcriptional regulator T-bet and expression of the T~H~1 gene program, while IL-6- or IL-21-dependent activation of STAT3 and up-regulation of the transcriptional repressor Bcl-6 play important roles in T~FH~ cell differentiation^[@CR4]--[@CR11]^.

Early work regarding T~H~1 and T~FH~ cells suggested that static populations of these cells developed in parallel during immune responses. However, it is now generally accepted that many T helper cell subsets are subject to phenotypic plasticity driven by signals from complex cytokine milieus during the course of an immune response^[@CR12]--[@CR18]^. With regard to T~FH~ populations, recent reports from both murine and human studies describe 'hybrid' T~FH~ cells that exhibit both B cell helper activity and secretion of effector cytokines normally expressed by other T helper subsets^[@CR19]^. These include T~H~1-biased 'T~FH1~' cells, which are capable of producing the T~H~1 cytokine IFN-γ in addition to IL-21. These cells have been identified as important responders in murine infection models, and have also been described in humans infected with HIV, mycobacterium tuberculosis, and plasmodium, among other pathogens^[@CR20]--[@CR27]^. Additionally, cell populations phenotypically similar to T~FH1~ cells have been implicated in the onset of autoimmune disease, including systemic lupus erythematosus^[@CR28]^. To date, however, the origin of these cells, including the regulatory mechanisms that direct both their differentiation and function, remains enigmatic.

Here, we describe the step-by-step *in vitro* differentiation of a murine T~H~1-derived, T~FH1~-like cell population that exhibits phenotypic and functional characteristics similar to T~FH1~ cells observed *in vivo*, in both murine and human settings. Specifically, these cells express elevated levels of Cxcr3 and are capable of producing both IFN-γ and IL-21. Interestingly, we find that T~FH1~-like cells provide B cell help similar to conventional T~FH~-like cells generated in the presence of IL-6. Mechanistically, we find that the differentiation and function of T~FH1~-like cells requires IL-12-dependent activation of both STAT4 and STAT3, which cooperatively drive the expression of both Bcl-6 and IL-21. Finally, and somewhat surprisingly, we found that while STAT3 activation required signals from IL-12, it was independent of autocrine IL-21 signaling. Taken together, the findings presented here provide insight into the potential origin and differentiation requirements of recently described T~FH1~ cell populations that have increasingly recognized roles in host immune responses and autoimmune disease.

Results {#Sec2}
=======

T~H~1-derived T~FH1~-like cells express both T-bet and Bcl-6 {#Sec3}
------------------------------------------------------------

Increasing evidence suggests that T~FH~ cells exhibit considerable heterogeneity, and that phenotypically distinct T~FH~ subsets arise in response to diverse immune challenges. These include T~H~1-biased T~FH1~ cells, which secrete the cytokines IFN-γ and IL-21 and express the chemokine receptor Cxcr3^[@CR25],[@CR29]^. While T~FH1~ cells have been observed in a number of clinical and experimental settings *in vivo*, the regulatory mechanisms underlying their development remain unclear^[@CR20],[@CR22],[@CR27],[@CR29]^. A previous study from our laboratory demonstrated that T~H~1 cells upregulate a T~FH~-like gene program in response to decreased signals from environmental IL-2 (Supplementary Fig. [1A](#MOESM1){ref-type="media"} and^[@CR17]^). These findings were in agreement with several other studies demonstrating that IL-2 signaling is a potent repressor of T~FH~ cell differentiation^[@CR30]--[@CR32]^. Given the T~H~1 origin of this T~FH~-like population, we sought to determine whether these cells were phenotypically and functionally similar to T~FH1~ cells described *in vivo*.

A hallmark feature of T~FH~ cell populations is their elevated expression of the transcriptional repressor Bcl-6^[@CR33]--[@CR35]^. As such, we began by comparing Bcl-6 expression in *in vitro*-differentiated murine T~H~1 cells, T~H~1-derived T~FH~-like ('T~FH1~-like') cells, previously described conventional T~FH~-like cells differentiated in the presence of IL-6 ('T~FH0~-like'), and non-polarized T~H~0 cells^[@CR36]^ (Fig. [1A](#Fig1){ref-type="fig"}). Relative to T~H~1 and T~H~0 cells, both T~FH1~-like and T~FH0~-like populations displayed elevated expression of the T~FH~ lineage-defining transcription factor Bcl-6 at both the transcript and protein level (Fig. [1B,C](#Fig1){ref-type="fig"}). In contrast, the Bcl-6 antagonist Blimp-1 was highly expressed only in the T~H~1 cell population (Fig. [1B](#Fig1){ref-type="fig"}). In addition to Bcl-6, T~FH1~ cells have also been shown to express the T~H~1 lineage-defining transcription factor T-bet^[@CR18],[@CR37]^. As such, we next assessed T-bet expression levels across the above cell populations. Indeed, both transcript and protein analyses revealed that only the T~FH1~-like population expressed both T-bet and Bcl-6 (Fig. [1B,C](#Fig1){ref-type="fig"}). Collectively, these data demonstrate that T~H~1-derived T~FH1~-like cells express both Bcl-6 and T-bet similar to findings from T~FH1~ cells observed *in vivo*^[@CR18],[@CR37]^.Figure 1TFH1-like cells derived from TH1 cells uniquely co-express Bcl-6 and T-bet. (**A**) Schematic depicting culturing conditions utilized for the differentiation of the indicated cell populations. Briefly, naïve CD4^+^ T cells were cultured on plate-bound anti-CD3 and anti-CD28 as follows: T~H~1 (5 ng/mL IL-12, 5 μg/mL anti-IL-4), T~FH0~-like (50 ng/mL IL-6, 10 μg/mL anti-IL-4, 10 μg/mL anti-IFN-γ), or T~H~0 (10 μg/mL anti-IL-4, 10 μg/mL anti-IFN-γ). After 3 days, cells were removed from stimulation and plated under the following conditions: T~H~1 (5 ng/mL rmIL-12, 2.5 μg/mL anti-IL-4, 500 U/mL rhIL-2), T~FH1~-like (expanded from T~H~1 population; 5 ng/mL rmIL-12, 2.5 μg/mL anti-IL-4, 10 U/mL rhIL-2), T~FH0~-like (10 μg/mL anti-IL-4, 10 μg/mL anti-IFN-γ, 50 ng/mL rmIL-6, 10 U/mL rhIL-2), or T~H~0 (10 μg/mL anti-IL-4, 10 μg/mL anti-IFN-γ, 10 U/mL IL-2) for an additional 2 days. (**B**) qRT-PCR was used to assess expression of the indicated genes. The data were normalized to *Rps18* and presented as fold change relative to the T~FH1~-like sample (mean of *n* = 4--7 ± s.e.m.). \*\**P* \< 0.01, \*\*\**P* \< 0.001; one-way ANOVA with Tukey multiple-comparison test. (**C**) Immunoblot analysis of Bcl-6 and T-bet protein expression in the indicated T helper cell populations. β-actin serves as a loading control. Shown is a representative blot of four independent experiments.

T~FH1~-like cells express elevated levels of Cxcr3, ICOS, and CD40 ligand {#Sec4}
-------------------------------------------------------------------------

A second distinguishing feature of T~FH1~ cells found *in vivo* is elevated surface expression of the chemokine receptor Cxcr3^[@CR24],[@CR25]^. Indeed, gene expression analysis demonstrated that T~FH1~-like cells had elevated levels of *Cxcr3* expression compared to their T~H~1 cell counterparts (Supplementary Fig. [1B](#MOESM1){ref-type="media"}). Therefore, we next used flow cytometric analysis to determine the relative expression of Cxcr3 on the surface of T~FH1~-like and T~FH0~-like populations. Indeed, T~FH1~-like cells exhibited significantly more surface expression of Cxcr3 compared to the T~FH0~ population (Fig. [2A](#Fig2){ref-type="fig"}). Interestingly, two cell surface proteins that are critical for the B cell helper activity of T~FH~ cells, ICOS and CD40 ligand, were also more highly expressed on T~FH1~-like cells (Fig. [2B,C](#Fig2){ref-type="fig"}). To determine whether there were further differences in expression of the T~FH~ gene program between the T~FH1~- and T~FH0~-like populations, we performed additional transcript analyses and found that, while there was no significant difference in the expression of *Bcl6* or *Btla*, a number of other T~FH~-associated genes, including the chemokine receptor *Cxcr5*, were more highly expressed in the T~FH0~-like population (Fig. [1A](#Fig1){ref-type="fig"} and Supplementary Fig. [2A,B](#MOESM1){ref-type="media"}). Conversely, as with ICOS and CD40 ligand, T~FH1~-like cells expressed significantly higher levels of T~FH~ genes known to be critical for effective B cell helper activity (Supplementary Fig. [2C](#MOESM1){ref-type="media"}). Taken together, these findings demonstrate that T~FH1~-like cells preferentially express Cxcr3 alongside a number of proteins required to provide T cell help to B cells.Figure 2T~FH1~-like cells express elevated levels of Cxcr3, ICOS, and CD40 ligand. (**A**) Flow cytometry analysis of Cxcr3 surface expression on the indicated T helper cell populations. Mean fluorescence intensity (MFI) is also shown (mean of *n* = 3 ± s.e.m.). (**B**) Flow cytometry analysis of ICOS and CD40 ligand surface expression by the indicated T helper cell populations. Mean fluorescence intensity (MFI) is also shown (mean of *n* = 5--6 ± s.e.m.). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001; one-way ANOVA with Tukey multiple-comparison test.

T~FH1~-like cells produce both IFN-γ and IL-21 {#Sec5}
----------------------------------------------

A functional characteristic of T~FH1~ cell populations is their expression of both IL-21 and IFN-γ^[@CR29],[@CR38]^. To determine whether T~FH1~-like cells similarly exhibit this function, we evaluated their ability to simultaneously produce IL-21 and IFN-γ via flow cytometry. While both T~FH1~-like and T~FH0~-like populations expressed IL-21, T~FH1~-like cells were superior producers of IFN-γ (Fig. [3A,B](#Fig3){ref-type="fig"}). Importantly, a significantly higher percentage of T~FH1~-like cells were IFN-γ^+^IL-21^+^, as compared to the T~FH0~-like population (Fig. [3C](#Fig3){ref-type="fig"}). Interestingly, we did not observe significant differences in the expression of either IFN-γ or IL-21 between T~H~1 and T~FH1~-like cells (Supplementary Fig. [1C](#MOESM1){ref-type="media"}). This was interesting, as it has been reported that IFN-γ expression is subject to Bcl-6-dependent repression during the differentiation of conventional T~FH~ cell populations^[@CR35]^. Collectively, these data demonstrate that in addition to exhibiting a T~FH1~ phenotype, T~H~1-derived T~FH1~-like cells also exhibit functional characteristics associated with T~FH1~ cells in the form of dual production of IFN-γ and IL-21^[@CR18],[@CR25]^.Figure 3T~FH1~-like cells express both IFN-γ and IL-21. (**A**) qRT-PCR analysis of *Ifng* and *Il21* expression in the indicated cell populations following stimulation with PMA/Ionomycin for 2.5 hrs. The data were normalized to *Rps18* and presented as fold change relative to the T~FH1~-like sample (mean of *n* = 5 ± s.e.m.). (**B**) Flow cytometry analysis of intracellular expression of IL-21 and IFN-γ in the indicated cell populations. Shown are representative data from four independent experiments. (**C**) Percentage of IFN-γ^+^IL-21^+^ cells as assessed by flow cytometry analysis (mean of *n* = 4 ± s.e.m.). \*\**P* \< 0.01, \*\*\**P* \< 0.001; one-way ANOVA with Tukey multiple-comparison test.

T~FH1~-like cells are capable of activating B cells and inducing antibody production {#Sec6}
------------------------------------------------------------------------------------

To extend our functional analyses, we next compared B cell helper activity between the two T~FH~-like populations. Consistent with their increased IL-21 production and expression of T~FH~ cell markers, both T~FH~-like cell populations were more effective at promoting B cell activation than non-polarized T~H~0 cells (Fig. [4A,B](#Fig4){ref-type="fig"}). Furthermore, co-culture experiments demonstrated that both T~FH~-like populations were capable of inducing antibody production by B cells, while T~H~0 cells were poor providers of B cell help (Fig. [4C](#Fig4){ref-type="fig"}). Interestingly, we did not observe differences in the ability of T~FH0~-like and T~FH1~-like cells to preferentially induce isotype switching. This may be due to the presence of multiple cytokines in the culture media, including both IL-21 and IFN-γ, as well as others that were not analyzed (e.g. IL-10). Regardless, our data support a functional role for T~FH1~-like cells, similar to that of T~FH0~-like cells, in supporting B cell antibody production (Fig. [4C](#Fig4){ref-type="fig"}). Together, these data demonstrate that T~H~1-derived T~FH1~-like cells are capable of performing functions attributed to *bona fide* T~FH~ cells and, interestingly, are functionally similar to more conventional IL-6-derived T~FH~ cells^[@CR19],[@CR25],[@CR27]^.Figure 4T~FH1~-like cells activate B cells and induce antibody production. (**A**) B cells were cultured with the indicated cell population (3:1 B/T ratio) and activation status was assessed by flow cytometry analysis of GL7 and FAS expression. Shown is representative data from five independent experiments. (**B**) The percentage of activated B cells (FAS^+^GL7^+^ cells) as assessed by flow cytometry in 'A' (mean of *n* = 5 ± s.e.m.). (**C**) ELISA analysis of antibody production by B cells cultured with the indicated cell population (3:1 B/T ratio) for 5 days (mean OD of *n* = 5 ± s.e.m.). \*\**P* \< 0.01, \*\*\**P* \< 0.001; one-way ANOVA with Tukey multiple-comparison test.

T~FH~ gene expression patterns and B cell helper activity are dependent upon IL-12 {#Sec7}
----------------------------------------------------------------------------------

We next sought to determine specific cytokine signals and transcription factors responsible for driving the T~FH1~-like phenotype. A notable difference between the T~FH1~-like and T~FH0~-like cell populations is that the T~H~1-derived T~FH1~-like cells are cultured in the presence of IL-12, rather than IL-6. While IL-12 has been reported to be an important factor in the *in vitro* and *in vivo* differentiation of human T~FH~ cell populations, the role of IL-12 in promoting murine T~FH~ cell differentiation is less clear^[@CR39]--[@CR42]^. In order to assess the role of IL-12 in T~FH1~-like cell differentiation, we cultured T~FH1~-like cells with and without IL-12 and assessed their expression of notable T~FH1~ cell transcription factors and cell surface receptors. Strikingly, expression of both T-bet and Bcl-6 was significantly reduced in the absence of IL-12 (Fig. [5A,B](#Fig5){ref-type="fig"}). Additional analyses revealed that while many T~FH~ genes were unaffected by the loss of IL-12, the expression of the key T~FH~-associated gene *Icos* was significantly reduced at both the transcript and protein level (Supplementary Fig. [3](#MOESM1){ref-type="media"}).Figure 5IL-12 signaling promotes Bcl-6, IL-21, and ICOS expression in T~FH1~-like cells. (**A**) qRT-PCR to assess expression of the indicated genes in T~FH1~-like cells cultured with (teal bars) or without (white bars) IL-12. The data were normalized to *Rps18* and presented as fold change relative to T~FH1~-like cells cultured with IL-12 (mean of *n* = 3 ± s.e.m.). (**B**) Immunoblot analysis of Bcl-6 protein expression in T~FH1~-like cells cultured with or without IL-12. Shown is a representative blot of three independent experiments. β-actin was used as a loading control. (**C**) qRT-PCR to assess expression of the indicated genes in T~FH1~-like cells cultured with (blue bars) or without (white bars) IL-12. The data were normalized to *Rps18* and presented as fold change relative to T~FH1~-like cells cultured with IL-12 (mean of *n* = 3 ± s.e.m.). (**D**) Flow cytometry analysis of intracellular expression of IL-21 and IFN-γ in T~FH1~-like cells cultured with or without IL-12. Shown is representative data from four independent experiments. (**E**) The percent of IFN-γ^+^IL-21^+^ cells as assessed by flow cytometry analysis in 'D' (mean of *n* = 4 ± s.e.m.). (**F**) ELISA analysis of IgM production by B cells co-cultured with the indicated T~FH1~-like population at a 3:1 B/T cell ratio for 5 days (mean OD of *n* = 3 ± s.e.m.). \*\**P* \< 0.01, \*\*\**P* \< 0.001; unpaired Student's *t*-test.

We next wanted to assess the importance of IL-12 signaling to T~FH1~-like cell function. As such, we assessed the ability of T~FH1~-like cells cultured in the presence and absence of IL-12 to produce cytokines and induce B cell-mediated antibody production. Importantly, production of IL-21 and IFN-γ, as well as the percentage of IFN-γ^+^IL-21^+^ cells, was reduced in the absence of signals from IL-12 (Fig. [5C--E](#Fig5){ref-type="fig"}). Furthermore, T~FH1~-like cells cultured without IL-12 were poor inducers of B cell antibody production as compared to IL-12-cultured controls (Fig. [5F](#Fig5){ref-type="fig"}). Taken together, these data demonstrate that IL-12 signaling is a potent inducer of the phenotypic and functional properties of T~FH1~-like cells.

STAT4 and STAT3 associate with the *Bcl6* and *Il21* loci downstream of IL-12 signaling {#Sec8}
---------------------------------------------------------------------------------------

We next sought to identify transcription factors downstream of IL-12 signaling that may regulate expression of key T~FH~ genes in T~FH1~-like cells. We began by focusing on STAT4, which is activated (phosphorylated) downstream of signals from IL-12 (Fig. [6A](#Fig6){ref-type="fig"}). A previous study described STAT4 association with the *Bcl6* and *Il21* loci^[@CR42]^. Indeed, we observed increased STAT4 enrichment at both the *Bcl6* and *Il21* promoters in T~FH1~-like cells cultured in the presence of IL-12, as compared to cells cultured without IL-12 (Fig. [6B--D](#Fig6){ref-type="fig"}). These findings suggest that STAT4 is a positive regulator of both Bcl-6 and IL-21 expression in T~FH1~-like cells.Figure 6IL-12 signaling results in increased association of STAT4 and STAT3 with the *Bcl6* and *Il21* loci. (**A**) Immunoblot analysis to assess STAT4 activation (pSTAT4 Y693) in T~FH1~-like cells cultured with or without IL-12. STAT4 and β-actin serve as controls for total STAT4 and equal protein loading, respectively. Shown is a representative blot of three independent experiments. (**B**) Schematic depicting the location of amplicons within the *Bcl6* and *Il21* gene loci utilized for ChIP analyses. (**C**,**D**) ChIP assays to evaluate STAT4 enrichment at the *Bcl6* and *Il21* loci in T~FH1~-like cells cultured with or without IL-12. Data are presented as percent enrichment relative to a "total" input sample (mean of *n* = 4 ± s.e.m.). (**E**) Immunoblot analysis of activated STAT3 (pSTAT3 Y705) in T~FH1~-like cells cultured with or without IL-12. STAT3 and β-actin are shown as controls for total STAT3 and equal protein loading, respectively. Shown is a representative blot from three independent experiments. (**F**,**G**) ChIP assays to quantify STAT3 enrichment at the *Bcl6* and *Il21* loci in T~FH1~-like cells cultured with or without IL-12. Data are presented as percent enrichment relative to a "total" input sample (mean of *n* = 4 ± s.e.m.). \**P* \< 0.05, \*\**P* \< 0.01; unpaired Student's *t*-test.

In addition to STAT4, STAT3 has also been identified as an important positive regulator of T~FH~ gene expression^[@CR5],[@CR17],[@CR43],[@CR44]^. STAT3 is activated in response to signaling from a number of cytokines including IL-21. Our previous findings demonstrated that IL-12 signaling was a potent driver of IL-21 expression by the T~FH1~-like population. As such, we considered the possibility that STAT3 activation may also require upstream signals from IL-12 in T~FH1~-like cells. Indeed, we found that STAT3 activation was reduced in the absence of IL-12 (Fig. [6E](#Fig6){ref-type="fig"}). Consistent with these data, we observed decreased STAT3 enrichment at the *Bcl6* and *Il21* promoters in T~FH1~-like cells cultured without IL-12 (Fig. [6F,G](#Fig6){ref-type="fig"}). We next sought to determine whether the observed STAT3 activation was due to IL-12-dependent, autocrine IL-21 signaling. However, we observed no difference in STAT3 activation or in the expression of Bcl-6 when IL-21R-deficient cells were differentiated under T~FH1~-like polarizing conditions, suggesting that STAT3 activation downstream of IL-12 signals was independent of IL-21 (Supplementary Figs. [4A--C](#MOESM1){ref-type="media"}). Collectively, these data implicate cooperative, IL-12-dependent activities of both STAT4 and STAT3 in the differentiation and functional regulation of T~FH1~-like cells.

Discussion {#Sec9}
==========

Recent work has established that T~H~1-biased T~FH~ cell populations exist *in vivo* and that these cells play roles in both healthy immune responses and autoimmune disease^[@CR20],[@CR24],[@CR25],[@CR28],[@CR29]^. To date, the cytokine signals and transcriptional mechanisms underlying their formation and function are unclear. Here, we demonstrate that *in vitro*-generated T~H~1 cells are capable of differentiating into a T~FH1~-like cell population that exhibits phenotypic and functional characteristics associated with T~FH1~ cells. Similar to T~FH1~ cells described *in vivo*, T~FH1~-like cells express both the T~FH~ lineage-defining factor Bcl-6 and the T~H~1 lineage-defining factor T-bet, in addition to the chemokine receptor Cxcr3. Functionally, our findings demonstrate that the T~FH1~-like cell population is capable of producing both IFN-γ and IL-21 and providing help to B cells that results in B cell activation and antibody production.

While there is a general consensus on the phenotypic and functional properties of T~FH1~ cells, there is still a debate as to their cellular origin. The findings presented here support a developmental pathway wherein T~H~1 cells give rise to a hybrid T~FH1~-like cell state by inducing the expression of Bcl-6 and other aspects of the T~FH~ gene program. In agreement with our findings, a recent report demonstrated that IFN-γ-producing T~FH~ cells generated *in vivo* require prior expression of T-bet^[@CR37]^. Alternatively, it has been suggested that T~FH1~ cells are conventional T~FH~ cells that gain T-bet expression and the ability to produce IFN-γ^[@CR29]^. While our work does not necessarily support this model, it is important to note that our findings also do not exclude this as a potential mechanism. Future studies will be necessary to determine whether a dominant differentiation pathway for T~FH1~ cells exists or whether there may be multiple origins from which these specialized T~FH~ cell populations arise.

Our current findings also provide mechanistic insight into the potential cytokine signals and downstream transcriptional mechanisms required for the differentiation of T~FH1~ cells. In this regard, we find that the expression of a number of genes that promote induction of the T~FH1~-like cell state is dependent upon signals from the cytokine IL-12. Specifically, we find that IL-12 is required for the elevated expression of Bcl-6 and ICOS that is observed in the T~FH1~-like population, as well as the production of IFN-γ and IL-21. These data are in agreement with previous work in human cells demonstrating that IL-12 is required for the development of a CD4^+^ T cell population that co-expresses IFN-γ and IL-21^[@CR26]^. Furthermore, our findings are also in agreement with work identifying a role for IL-12 in positively regulating the development and function of human T~FH~ cells in both *in vitro* and *in vivo* settings^[@CR40],[@CR41],[@CR43],[@CR45]^.

Interestingly, while the role of IL-12 in human T~FH~ cell development is relatively well defined, the requirement for IL-12 signals in murine T~FH~ differentiation is less clear^[@CR16],[@CR18],[@CR42]^. As a potential explanation for this discrepancy, we find that while IL-12 signaling in the form of STAT4 and STAT3 activation is required to drive the expression of a subset of T~FH~ genes, including *Bcl6*, *Icos*, and *Il21*, signals from IL-12 appear to play a complementary but secondary role to those derived from IL-2^[@CR17]^. Thus, our findings support a model wherein combined IL-12 and IL-2 signals drive T~H~1 cell differentiation, while IL-12 signals in the absence of strong IL-2 signaling promote the alternative T~FH1~-like phenotype. Indeed, our previous work, and that of others, has demonstrated that the IL-2/STAT5 signaling axis functions as a potent negative regulator of T~FH~ cell development^[@CR17],[@CR30]--[@CR32]^.

Intriguingly, our work implicates an IL-12/STAT4/STAT3 signaling axis in the positive regulation of T~FH1~ cell development, as IL-12 signaling is required for both STAT4 and STAT3 activation in the T~FH1~-like population. In agreement with these findings, STAT4 activation has been previously implicated in the generation of IFNγ-producing T-bet^+^Bcl-6^+^ T~FH~ cells generated in response to viral infection^[@CR18]^. Though our findings suggest that IL-12-dependent activation of STAT3 promotes the expression of the T~FH1~ phenotype, the identity of the signals that drive the phosphorylation of STAT3 remain unclear. Classically, IL-12 signaling has been associated with STAT4 activation. However, previous work has indicated that IL-12 signals are also capable of inducing STAT3 activation^[@CR46]^. We also considered the possibility that STAT3 activation may arise from autocrine IL-21 signaling. However, experiments with IL-21R^−/−^ T cells demonstrated that STAT3 activation is independent of IL-21. Thus, whether STAT3 activation is occurring directly downstream of IL-12 signaling, or downstream of signals from an IL-12-dependent cytokine, is as yet unclear.

Collectively, the work presented here supports a possible T~H~1 origin for the T~FH1~ cells observed *in vivo*, and also provides insights into the regulatory requirements that govern their development. Given their role in infection and autoimmune disease, a better understanding of such regulatory requirements may identify potential therapeutic targets, which will allow for more selective manipulation of T~FH1~ cell populations in efforts to treat human disease.

Methods {#Sec10}
=======

Primary cells and cell culture {#Sec11}
------------------------------

All mouse strains \[C57BL/6J, C57BL/6NJ, IL-21R^−/−^ (C57BL/6NJ background)\] were obtained from the Jackson Laboratory. Naïve CD4^+^ T cells were purified from the spleens and lymph nodes of 5--8 week old mice via negative selection using the BioLegend Mojosort kit according to the manufacturer's instructions. For all experiments, cells were cultured in complete IMDM ("cIMDM": IMDM \[Life Technologies\], 10% FBS \[Life Technologies\], 1% Penicillin-Streptomycin \[Life Technologies\], and 50 μM β-mercaptoethanol \[Sigma-Aldrich\]). Following isolation, cells were plated at a density of 3--5 × 10^5^ cells per well and stimulated using plate-bound anti-CD3ε (5 µg/ml; BD Biosciences) and anti-CD28 (10 μg/ml; BD Biosciences) under the following polarizing conditions: T~H~1 (5 ng/mL rmIL-12 \[R&D Systems\], 5 μg/mL anti-IL-4), T~FH0~-like (10 μg/mL anti-IFN-γ, 10 μg/mL anti-IL-4, 50 ng/mL rmIL-6 \[R&D Systems\]), T~H~0 (10 μg/mL anti-IFN-γ \[XMG1.2; BioLegend\], 10 μg/mL anti-IL-4 \[11B11; BioLegend\]). After 3 days, cells were removed from stimulation and expanded to plate at 5--7 × 10^5^ cells/well in fresh media under the following conditions: T~H~1 (5 ng/mL rmIL-12, 2.5 μg/mL anti-IL-4, 500 U/mL rhIL-2 \[NIH\]), T~FH1~-like (expanded from T~H~1 population; 5 ng/mL rmIL-12, 2.5 μg/mL anti-IL-4, 10 U/mL rhIL-2), T~FH0~-like (10 μg/mL anti-IFN-γ, 10 μg/mL anti-IL-4, 50 ng/mL rmIL-6, 10 U/mL rhIL-2), T~H~0 (10 μg/mL anti-IFN-γ, 10 μg/mL anti-IL-4, 10 U/mL IL-2) for an additional 48 h. Where indicated, IL-12 was omitted from the T~FH1~-like culturing conditions. The Institutional Animal Care and Use Committee of Virginia Tech approved all experiments involving the use of mice. All methods were performed in accordance with the approved guidelines.

T and B cell co-culture and analysis of helper activity {#Sec12}
-------------------------------------------------------

B cells were purified from the spleens and lymph nodes of age- and sex-matched 5--8 week old C57BL/6J mice using the MojoSort Mouse Pan B cell isolation kit (BioLegend), according to the manufacturer's instructions. For each indicated population, 1 × 10^5^ T cells were mixed with B cells at a 1:3 T cell:B cell ratio and stimulated using plate-bound anti-CD3ε (5 μg/mL) under T~FH1~-like or T~FH0~-like conditions. Where indicated, IL-12 was omitted from the T~FH1~-like conditions. T and B cells were co-cultured for either 2 days, at which point B cell activation was analyzed by flow cytometry, or 4 days, where supernatant was collected for ELISA analysis of antibody production.

Antibody production was measured using the BD Pharmingen Mouse Immunoglobulin Isotyping ELISA kit according to the manufacturer's instructions. OD450 values were calculated by subtracting OD450 readings taken from supernatants from B cells cultured alone in the indicated polarizing conditions from the OD450 values of co-cultured samples.

RNA isolation and qRT-PCR {#Sec13}
-------------------------

RNA was purified using the NucleoSpin RNA Kit (Macherey-Nagel). Complementary DNA was generated using the Superscript IV First Strand Synthesis System (Thermo Fisher). qRT-PCR reactions were performed with 10--20 ng cDNA per reaction, gene-specific primers (*Rps18* forward: 5′-GGAGAACTCACGGAGGATGAG-3′, *Rps18* reverse: 5′-CGCAGCTTGTTGTCTAGACCG-3′; *Bcl6* forward: 5′-CCAACCTGAAGACCCACACTC-3′, *Bcl6* reverse: 5′-GCGCAGATGGCTCTTCAGAGTC-3′; *Tbx21* forward: 5′-GTGACTGCCTACCAGAACGC-3′, *Tbx21* reverse: 5′-AGGGGACACTCGTATCAACAG-3′; *Il21* forward: 5′-TGGATCCTGAACTTCTATCAGCTCC-3′, *Prdm1* forward: 5′-CTTGTGTGGTATTGTCGGGAC-3′, *Prdm1* reverse: 5′-CACGCTGTACTCTCTCTTGG-3′; *Il21* reverse: 5′-AGGCAGCCTCCTCCTGAGC-3′; *Ifng* forward: 5′-CTACCTTCTTCAGCAACAGC-3′, *Ifng* reverse: 5′-GCTCATTGAATGCTTGGCGC-3′; *Il21* forward: 5′- TGGATCCTGAACTTCTATCAGCTCC, *Il21* reverse: 5′- AGGCAGCCTCCTCCTGAGC; *Cxcr5* forward: 5′-GTACCTAGCCATCGTCCATGC-3′, *Cxcr5* reverse: 5′-GTGCACTGTGGTAAGGAGTCG-3′; *Btla* forward: 5′-CATCCCAGATGCCACCAATGC-3′, *Btla* reverse: 5′-CAGAAAGCAGAGCAGGCAGAC-3′; *Icos* forward: 5′-CTCACCAAGACCAAGGGAAGC-3′, *Icos* reverse: 5′-CCACAACGAAAGCTGCACACC-3′; *Cd40l* forward: 5′-AGCCAACAGTAATGCAGCATCCG-3′, *Cd40l* reverse: 5′-AGCCAGAGGCCGACGATGAATG-3′; *Sh2d1a* forward: 5′-CTGGATGGAAGCTATCTGCTG-3′, *Sh2d1a* reverse: 5′-CAGGTGCTGTCTCGGCACTCC-3′; *Il6ra* forward: 5′-CCACATAGTGTCACTGTGCG-3′, *Il6ra* reverse: 5′-GGTATCGAAGCTGGAACTGC-3′; *Tnfsf8* forward: 5′-GCAGCTACTTCTACCTCAGCAC-3′, *Tnfsf8* reverse: 5′-GTGCCATCTTCGTTCCATGACAG-3′; *Pdcd1* forward: 5′-CGTCCCTCAGTCAAGAGGAG-3′, *Pdcd1* reverse: 5′-GTCCCTAGAAGTGCCCAACA-3′; *Cxcr3* forward: 5′- CCTTGAGGTTAGTGAACGTC-3′, *Cxcr3* reverse: 5′-GCTGGCAGGAAGGTTCTGTC-3′) and SYBR Select Mastermix (Life Technologies). All samples were normalized to *Rps18* as a control and are presented either as mRNA relative to *Rps18*, or as fold change relative to the control sample, as indicated. To measure *Il21* and *Ifng* transcript expression, the indicated T helper populations were re-stimulated with PMA and Ionomycin for 2.5--4 h.

Immunoblot analyses {#Sec14}
-------------------

Immunoblot analyses were performed as described previously^[@CR44]^. Antibodies used to detect chosen proteins were as follows: Bcl-6 (1:500, BD Pharmingen), T-bet (1:1,000, Santa Cruz), pSTAT3 Y705 (1:20,000, Abcam), STAT3 (1:5000, Santa Cruz), pSTAT4 Y693 (1:1000, Cell Signaling), and STAT4 (1:2500, BioLegend). For all experiments, β-actin (1:15,000, GenScript) expression was monitored to ensure equivalent protein loading. Original and uncropped images of immunoblots can be found in Supplementary Fig. [5](#MOESM1){ref-type="media"}.

Flow cytometry {#Sec15}
--------------

For extracelluar epitopes, cells were harvested and washed 1x with FACS buffer (PBS w/2% FBS, 1% BSA) prior to staining with flurochrome-conjugated anti-ICOS PE (eBioscience), anti-CD40lg PE (Biolegend), anti-Cxcr3 PE (Biolegend), anti-FAS BV421 (BD Bioscience), anti-GL7 AF488 (BD Bioscience), anti-CD4 AF488 (R&D), anti-B220 PECy7 (BD Bioscience), anti-IL21R PE (Biolegend), or the appropriate isotype control. Cells were incubated for 1 hour at room temperature and subsequently washed 2x with FACS buffer. Cell viability was determined by incubating the cells with either Sytox Blue (ThermoFisher) or Sytox Green (ThermoFisher). Samples containing B cells were subjected to Fc block anti-CD16/CD32 (Invitrogen). For cytokine staining, cells were treated with Golgi stop (BD Bioscience) and restimulated with PMA and Ionomycin for 2 h. Cells were fixed and permeablized using the BD Cytofix/Cytoperm kit as detailed by the manufacturer. Cells were incubated with IL-21R subunit/Fc chimera (R&D Systems), washed with Perm/Wash buffer (BD), stained with F(ab')2 anti-Human IgG Fc R-PE (Life Technologies), washed, and finally stained with anti-IFN-γ AF700 (R&D Systems). All incubations were carried out for 30 minutes at 4 °C. Goat F(ab')2 IgG R-PE (Life Technologies) and Rat IgG2a AF700 (R&D Systems) were used as isotype controls. Samples were analyzed on the BD Accuri C6 or the Sony SH800 flow cytometers and data evaluated using Flowjo software.

ChIP {#Sec16}
----

Chromatin was prepared from the indicated T helper cell population as previously described^[@CR17]^. The resulting chromatin was incubated with either anti-STAT4 (Santa Cruz), anti-STAT3 (Santa Cruz), or control antibody (Abcam) and immunoprecipitated using Protein G Dynabeads (Life Technologies). Precipitated DNA was analyzed via quantitative PCR using SYBR Select Mastermix (Life Technologies) and gene-specific primers: (*Bcl6* promoter forward: 5′-GCGGAGCAATGGTAA AGCCC-3′, and reverse: 5′-CTGGTGTCCGGCCTTTCCTAG-3′; *Bcl6* control forward: 5′-GTACTCCAACAACAGCACAGC-3′, and reverse: 5′-GTGGCTCGTTAAATCACAGAGG-3′; *Il21* promoter forward: 5′-CAC ACACCTTGGTGAATGCTG-3′, and reverse: 5′-CCATTGGCTAGGTGTACGTGTG-3′). Samples were normalized to total input followed by the subtraction of the isotype control to account for unspecific binding.

Statistical analyses {#Sec17}
--------------------

All data represent at least three independent experiments. Error bars represent the standard error of the mean. For statistical analysis, unpaired *t* tests or one-way ANOVA with Tukey multiple comparison tests were performed to assess statistical significance, as appropriate for a given experiment. *P* values \< 0.05 were considered statistically significant.
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